ALL EYES ON GILEAD
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Tag: Captisol
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Ligand CEO Issues Letter to Captisol Customers
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
The history of sulfobutylether-beta-cyclodextrin
With this historical paper, prof. Stella and Dr. Rajevski wanted to honor to Dr. Thornsteinn Loftsson, Professor Emeritus at University
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Japan to approve remdesivir for coronavirus patients in May
Prime Minister Shinzo Abe said Monday that Japan will soon approve the SBECD-eanbled anti-viral drug remdesivir for the treatment of
Gilead reports compassionate use data of remdesivir in Covid-19
Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential
Axsome Therapeutics’s SBECD-enabled AXS-07 Achieves Primary Endpoints and Prevents Migraine Pain Progression in Phase 3 Trial
Axsome Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that